Spruce Biosciences’ Compliance Plan Accepted by Nasdaq

Spruce Biosciences ( (SPRB) ) has shared an update.

Spruce Biosciences, Inc. faced a delisting notice from Nasdaq due to non-compliance with the minimum bid price requirement, resulting in the suspension of its common stock from Nasdaq on April 29, 2025. The company appealed this decision and submitted a compliance plan, which was accepted on June 9, 2025, allowing the stock to resume trading on Nasdaq if compliance is regained by August 5, 2025. The company is working to regain compliance, including proposing a reverse stock split at its annual meeting on July 22, 2025.

The most recent analyst rating on (SPRB) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Spruce Biosciences stock, see the SPRB Stock Forecast page.

Spark’s Take on SPRB Stock

According to Spark, TipRanks’ AI Analyst, SPRB is a Underperform.

Spruce Biosciences faces substantial financial challenges with declining revenues and persistent losses. Bearish technical indicators and unfavorable valuation metrics further weigh on the stock. The strategic acquisition of TA-ERT offers potential growth, but the financial instability remains a critical concern.

To see Spark’s full report on SPRB stock, click here.

More about Spruce Biosciences

Average Trading Volume: 1,406,116

Technical Sentiment Signal: Sell

Current Market Cap: $2.53M

For an in-depth examination of SPRB stock, go to TipRanks’ Stock Analysis page.